Grifols, S.A. (NASDAQ:GRFS – Get Rating)’s stock price was down 8.2% during trading on Wednesday after Berenberg Bank lowered their price target on the stock from €21.40 to €20.60. Berenberg Bank currently has a buy rating on the stock. Grifols traded as low as $10.66 and last traded at $11.29. Approximately 3,918 shares were traded during trading, a decline of 100% from the average daily volume of 914,807 shares. The stock had previously closed at $12.30.
Several other equities analysts have also issued reports on the stock. StockNews.com began coverage on shares of Grifols in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Morgan Stanley began coverage on shares of Grifols in a report on Friday, April 8th. They issued an “equal weight” rating on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $15.80.
Institutional investors and hedge funds have recently bought and sold shares of the business. JJJ Advisors Inc. increased its stake in Grifols by 106.2% in the fourth quarter. JJJ Advisors Inc. now owns 3,880 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,998 shares in the last quarter. Parallel Advisors LLC increased its stake in Grifols by 367.8% in the fourth quarter. Parallel Advisors LLC now owns 4,360 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 3,428 shares in the last quarter. Lindbrook Capital LLC increased its stake in Grifols by 657.5% in the fourth quarter. Lindbrook Capital LLC now owns 5,886 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 5,109 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Grifols by 40.0% in the first quarter. PNC Financial Services Group Inc. now owns 10,530 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 3,010 shares in the last quarter. Finally, JFS Wealth Advisors LLC increased its stake in Grifols by 23.3% in the fourth quarter. JFS Wealth Advisors LLC now owns 10,950 shares of the biotechnology company’s stock valued at $123,000 after purchasing an additional 2,071 shares in the last quarter. 14.71% of the stock is owned by hedge funds and other institutional investors.
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
The company has a quick ratio of 0.94, a current ratio of 1.59 and a debt-to-equity ratio of 1.06. The firm’s 50 day simple moving average is $12.12 and its two-hundred day simple moving average is $11.64. The stock has a market capitalization of $7.71 billion, a P/E ratio of 9.97 and a beta of 0.41.
About Grifols (NASDAQ:GRFS)
Grifols, SA engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Grifols right now?
Before you consider Grifols, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Grifols wasn’t on the list.
While Grifols currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Leave a Comment